Open Clinical Trials
A Phase II Trial of Dasatinib in Advanced Sarcomas
Phase: |
Phase II ( Phase 2 ) |
Trial for Patients with: |
Advanced sarcomas (see conditions below) |
Treatment involved: |
Drug taken twice daily by mouth |
Age Requirement: |
13 and older |
Location: |
Arkansas, California, District of Columbia, Georgia, Idaho, Illinois, Indiana, Maryland, Massachusetts, Michigan, Nebraska, Pennsylvania and Texas |
| Description | This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib. Subjects take Dasatinib twice daily by mouth for 28 days per 28 day cycle. Subjects will be seen for interim medical history, physical exam and laboratory studies prior to each cycle. Subjects will undergo tumor imaging every 2 months (8 weeks) for the first 6 months and approximately every 3 months thereafter while on treatment. A blood sample for collection of specimens with which to later study serum level of Dasatinib and effects on biomarkers of drug activity will be obtained approximately 2 to 4 weeks after the start of treatment. Central collection of archival tumor with which to later study the frequency of expression and/or mutation of kinases inhibited by dasatinib will occur. Subjects will be followed for approximately every 3 months until 2 years from registration and then approximately yearly until 5 years from registration. The total expected enrollment is 452 patients. |
| Conditions |
|
| Excluded conditions: | Liposarcoma and Leiomyosarcoma - no longer eligible |
| Trial Start Date: | May 2007 |
| Trial End Date: | December 2013 (estimated) |
| ClinicalTrials.gov: | NCT00464620 : detailed information at ClinicalTrials.gov |
| This page was last updated on: | March 23, 2009 |